Literature DB >> 30611643

National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer.

Adam B Weiner1, Oliver S Ko2, Alec Zhu2, Daniel E Spratt3, Jim C Hu4, Edward M Schaeffer2.   

Abstract

PURPOSE: Controversy surrounds the benefit of pelvic lymph node irradiation (PLN-RT) in localized prostate cancer (CaP). Our objective was to determine the practice patterns and predictors of PLN-RT in a national cohort.
MATERIALS AND METHODS: The National Cancer Data Base (2005-2015) was leveraged to obtain men diagnosed with nonmetastatic CaP treated with external beam radiotherapy (n = 197,378). Multivariable logistic regressions were used to assess temporal trends and factors associated with PLN-RT.
RESULTS: PLN-RT occurred in 37% of patients overall, which increased to 41% by 2015. When stratified by risk group, there was no significant difference in PLN-RT over time in low, favorable intermediate, unfavorable intermediate, or high-risk CaP. PLN-RT increased for men with very high-risk disease (51%-60%; odds ratio per year 1.34, 95% confidence inrerval 1.06-1.70, P = 0.013). Increased odds of PLN-RT was associated with higher risk disease, addition of hormone therapy, treatment at community hospitals, and shorter patient travel distance to treatment facilities. Surprisingly, 26% and 34% of low and favorable intermediate risk CaP received PLN-RT, respectively. Predictors of PLN-RT among these patients included treatment at a community practice and use of brachytherapy or hormone therapy.
CONCLUSIONS: PLN-RT occurred in about one-third of men receiving external beam radiotherapy and increased over time, mostly in men with very high-risk CaP for unclear reasons. Of concern, over one-quarter of low-risk men receive PLN-RT. Further work is needed to understand the heterogeneity in PLN-RT use. We await the completion of RTO G 09-24 to better understand the role of PLN-RT for men with localized CaP.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Epidemiology; Prostatic neoplasms; Radical prostatectomy; Radiotherapy; United States

Mesh:

Year:  2019        PMID: 30611643      PMCID: PMC6511330          DOI: 10.1016/j.urolonc.2018.12.022

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

1.  Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.

Authors:  Giovanna Mantini; Luca Tagliaferri; Gian Carlo Mattiucci; Mario Balducci; Vincenzo Frascino; Nicola Dinapoli; Cinzia Di Gesù; Edy Ippolito; Alessio G Morganti; Numa Cellini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

2.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Authors:  Mack Roach; Jennifer Moughan; Colleen A F Lawton; Adam P Dicker; Kenneth L Zeitzer; Elizabeth M Gore; Young Kwok; Michael J Seider; I-Chow Hsu; Alan C Hartford; Eric M Horwitz; Kosj Yamoah; Christopher U Jones; Jeff M Michalski; W Robert Lee; Thomas M Pisansky; Rachel Rabinovitch; Marvin Rotman; Rodger M Pryzant; Harold E Kim; Charles R Thomas; William U Shipley; Howard M Sandler
Journal:  Lancet Oncol       Date:  2018-10-10       Impact factor: 41.316

3.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

4.  Racial/ethnic differences in treatment discussed, preferred, and received for prostate cancer in a tri-ethnic population.

Authors:  G M Monawar Hosain; Maureen Sanderson; Xianglin L Du; Wenyaw Chan; Sara S Strom
Journal:  Am J Mens Health       Date:  2012-03-13

5.  Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.

Authors:  Pascal Pommier; Sylvie Chabaud; Jean-Leon Lagrange; Pierre Richaud; Elisabeth Le Prise; Jean-Philippe Wagner; David Azria; Veronique Beckendorf; Jean-Philippe Suchaud; Valerie Bernier; David Perol; Christian Carrie
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-15       Impact factor: 7.038

6.  Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Authors:  Jeff M Michalski; Jennifer Moughan; James Purdy; Walter Bosch; Deborah W Bruner; Jean-Paul Bahary; Harold Lau; Marie Duclos; Matthew Parliament; Gerard Morton; Daniel Hamstra; Michael Seider; Michael I Lock; Malti Patel; Hiram Gay; Eric Vigneault; Kathryn Winter; Howard Sandler
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

7.  Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.

Authors:  Michael J Zelefsky; Jennifer Moughan; Jean Owen; Anthony L Zietman; Mack Roach; Gerald E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

8.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Authors:  Colleen A Lawton; Michelle DeSilvio; Mack Roach; Valery Uhl; Robert Kirsch; Michael Seider; Marvin Rotman; Christopher Jones; Sucha Asbell; Richard Valicenti; Stephen Hahn; Charles R Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

9.  Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

Authors:  Pascal Pommier; Sylvie Chabaud; Jean Leon Lagrange; Pierre Richaud; François Lesaunier; Elisabeth Le Prise; Jean Philippe Wagner; Meng Huor Hay; Veronique Beckendorf; Jean Philippe Suchaud; Pierre Marie Pabot du Chatelard; Valerie Bernier; Nicolas Voirin; David Perol; Christian Carrie
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

10.  Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.

Authors:  Ayal A Aizer; James B Yu; Anne M McKeon; Roy H Decker; John W Colberg; Richard E Peschel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

View more
  1 in total

Review 1.  Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy.

Authors:  M Protopapa; V Kouloulias; A Kougioumtzopoulou; Z Liakouli; C Papadimitriou; A Zygogianni
Journal:  Clin Transl Oncol       Date:  2019-06-28       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.